Wang Y, Jiang X, Wang S
Clin Exp Obstet Gynecol. 2014;41(2):154-7.
To discuss the influence of mifepristone to caspase 3 expression in adenomyosis tissue.
Sixty patients were equally divided into four groups. Groups 1, 2, and 3 were treated with 5, 10, and 15 mg mifepristone, respectively and group 4 was treated with placebo. The expression of caspase 3 was examined by immunohistochemical method in both eutopic and ectopic endometria of the 40 cases.
Compared with placebo group, the expression of caspase 3 in both eutopic endometrium and ectopic endometrium in the three treatment groups was significantly increased. There was no difference in the expression of caspase 3 in both eutopic and ectopic endometria between the ten and 25 mg treatment groups, while both the ten and 25 mg treatment groups had a higher expression intensity of caspase 3 in both eutopic and ectopic endometria, compared with the five mg treatment group (p < 0.01).
Mifepristone can increase the expression of caspase 3 in both eutopic and ectopic endometria and initiate cell apoptosis in both eutopic and ectopic endometria. Therefore mifepristone can effectively inhibit the emergence and development of adenomyosis.
探讨米非司酮对子宫腺肌病组织中半胱天冬酶-3表达的影响。
60例患者平均分为四组。第1、2、3组分别给予5、10、15mg米非司酮治疗，第4组给予安慰剂治疗。采用免疫组织化学方法检测40例患者在位及异位内膜中半胱天冬酶-3的表达。
与安慰剂组相比，三个治疗组在位及异位内膜中半胱天冬酶-3的表达均显著增加。10mg与15mg治疗组在位及异位内膜中半胱天冬酶-3的表达无差异，但与5mg治疗组相比，10mg与15mg治疗组在位及异位内膜中半胱天冬酶-3的表达强度均较高（p<0.01）。
米非司酮可增加在位及异位内膜中半胱天冬酶-3的表达，启动在位及异位内膜细胞凋亡。因此，米非司酮可有效抑制子宫腺肌病的发生发展。
